August 14, 2024 August 14, 2024Categories Trial ResultsTrial Results: ECOG-ACRIN Research Round-UpSummaries of recently published ECOG-ACRIN research results
July 3, 2024 July 3, 2024Categories Trial ResultsTrial Results: ECOG-ACRIN Research Round-UpSummaries of recently published ECOG-ACRIN research results
June 11, 2024 June 11, 2024Categories Trial ResultsTrial Results: ECOG-ACRIN Research Round-Up – ASCO 2024 HighlightsSummaries of five ECOG-ACRIN trials presented at the 2024 American Society of Clinical Oncology Annual Meeting
May 1, 2024 May 1, 2024Categories Trial ResultsECOG-ACRIN Research at ASCO 2024Researchers with the ECOG-ACRIN Cancer Research Group will present a wide range of research findings at the 2024 ASCO Annual Meeting
May 1, 2024 May 1, 2024Categories Trial ResultsTrial Results: ECOG-ACRIN Research Round-UpSummaries of recently published ECOG-ACRIN research results
April 9, 2024 April 9, 2024Categories Trial ResultsTrial Results: ECOG-ACRIN Research Round-UpSummaries of recently published ECOG-ACRIN research results
March 7, 2024 March 7, 2024Categories Trial ResultsTrial Results: ECOG-ACRIN Research Round-UpSummaries of recently published ECOG-ACRIN research results
August 25, 2023 August 25, 2023Categories Trial ResultsTrial Results: ECOG-ACRIN Research Round-UpSummaries of recently published ECOG-ACRIN research results
June 30, 2023 June 30, 2023Categories Special Topics Trial ResultsGame, Set, (NCI-)MATCHAt a recent meeting, ECOG-ACRIN leaders and members celebrated the conclusion of enrollment to the landmark NCI-MATCH clinical trial
June 30, 2023 June 30, 2023Categories Active Clinical Trials Trial ResultsECOG-ACRIN and PrECOG Research at ASCO 2023Researchers presented numerous research abstracts and trial updates at the 2023 ASCO Annual Meeting
April 19, 2023 April 19, 2023Categories Trial ResultsTrial Results: ECOG-ACRIN Research Round-UpSummaries of recently published ECOG-ACRIN research results
February 10, 2023 February 10, 2023Categories Trial ResultsTrial Results: ASH Highlights Practice-Changing Results for B-Lineage Acute Lymphoblastic LeukemiaThe phase 3 E1910 clinical trial provides strong evidence for adding immunotherapy to standard front-line consolidation chemotherapy